Request Demo
Last update 16 May 2025
TQB-3454
Last update 16 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms CT-2755, TQB 3454 |
Target |
Action inhibitors |
Mechanism IDH1 inhibitors(Isocitrate dehydrogenase [NADP] cytoplasmic inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (China) |
Login to view timeline
Related
5
Clinical Trials associated with TQB-3454CTR20233533
TQB3454片在血液肿瘤患者中的Ib期临床试验
[Translation] Phase Ib clinical trial of TQB3454 tablets in patients with hematological malignancies
NCT06139367
A Randomized, Open, Parallel, Single Center Phase I Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetics of TQB3454 Tablets in Healthy Adult Subjects.
NCT05987358
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of TQB3454 Tablets in the Treatment of Advanced Biliary Tract Cancer With Isocitrate Dehydrogenase 1 (IDH1) Mutation.
100 Clinical Results associated with TQB-3454
Login to view more data
100 Translational Medicine associated with TQB-3454
Login to view more data
100 Patents (Medical) associated with TQB-3454
Login to view more data
100 Deals associated with TQB-3454
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced biliary tract cancer | Phase 3 | China | 05 Sep 2023 | |
| Hematologic Neoplasms | Phase 3 | - | - | |
| Acute Promyelocytic Leukemia | Phase 2 | China | 10 Jul 2023 | |
| Myelodysplastic Syndromes | Phase 2 | China | 10 Jul 2023 | |
| Relapsing acute myeloid leukemia | Phase 2 | China | 10 Jul 2023 | |
| Bile Duct Neoplasms | Phase 1 | China | 01 Nov 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 17 Aug 2020 | |
| IDH1 Mutation Cholangiocarcinoma | IND Approval | China | 22 Jun 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 36 | rxyvjlrkmm(jpzswaipgh) = None rygeitiqpy (soptesslsp ) | Positive | 27 Jun 2024 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free